Please login to the form below

Not currently logged in
Email:
Password:

ADC Therapeutics

This page shows the latest ADC Therapeutics news and features for those working in and with pharma, biotech and healthcare.

AZ buys into ADC sector with $440m Spirogen deal

AZ buys into ADC sector with $440m Spirogen deal

Both Spirogen and ADC Therapeutics are owned by private equity firm Auven Therapeutics. ... The cutting-edge technologies developed by Spirogen and ADC Therapeutics complement MedImmune's innovative antibody engineering capabilities," commented Jallal.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    465. Abzena. Not disclosed. Licence. ThioBridge ADC linker technology. 300. Domain Therapeutics.

  • Deal Watch February 2016 Deal Watch February 2016

    acquisition - company. 895. Mersana Therapeutics/ Takeda. XMT-1522, Fleximer-based ADC therapy targeting HER2-expressing tumours (preclinical) access to Fleximer ADC platform. ... acquisition - product. 190. Annapurna Therapeutics/ Avalanche

  • Pharma deals during October 2013 Pharma deals during October 2013

    ADC Therapeutics retains the option to co-promote one of the two products in the US. ... Auven's portfolio of companies includes Resolvyx, Kiacta, Kolitan and Sprout Pharmaceuticals, as well as Spirogen and ADC Therapeutics.

  • Pharma deals during April 2013 Pharma deals during April 2013

    respectively. As a result, companies with ADC capabilities, such as Ambrx, Mersana Therapeutics and ImmunoGen, are becoming popular partner targets for pharma companies. ... Santaris/ BMS. April also saw the announcement of yet another Santaris deal,

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • ADC Therapeutics expands team ADC Therapeutics expands team

    ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said: “ The quality of individuals and depth of experience that we

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics